secwatch.observer — SEC 8-K summary
======================================

Issuer:     UTAH MEDICAL PRODUCTS INC (UTMD)
CIK:        0000706698
Form:       8-K
Filed at:   2026-07-23T19:13:28+00:00
Accession:  0001096906-26-001112
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01, 99.1
LLM model:  deepseek-v4-flash:cloud@v2

UTMD Q2 2026 revenue down 14.3% to $8.5M; EPS $0.844 vs $0.939; cuts FY2026 guidance to -10-13% decline
--------------------------------------------------------------------------------

- Q2 2026 revenue $8.53M, down 14.3% from $9.95M in Q2 2025; 1H revenue $17.25M, down 12.3%.
- Diluted EPS $0.844 in Q2 2026 vs $0.939 in Q2 2025, a 10.1% decline; 1H EPS $1.661 vs $1.858.
- FY2026 revenue guidance cut to decline of 10-13% from prior expectation of flat; new product sales slower than expected.
- Litigation costs in 1H 2026 were $1.3M vs $1.0M in 1H 2025; now expects 2026 litigation <$1.6M vs prior <$1.355M.
- Cash and investments $87.5M, no debt; share repurchases minimal at $0.2M in 1H 2026 vs $6.7M in 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/706698/000109690626001112/0001096906-26-001112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/706698/000109690626001112/utmd-20260723_8k.htm
  HTML page:      https://secwatch.observer/filing/0001096906-26-001112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer